View in EDS

Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).

Saved in:
Bibliographic Details
Title: Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).
Authors: Hodges MR; Independent/Former Amplyx Pharmaceuticals Inc, San Diego, California, USA.; Pfizer Central Research and Development (PGRD), La Jolla, San Diego, California, USA., Tawadrous M; Clinical Development, Pfizer Inc, New York, New York, USA., Cornely OA; Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.; Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany., Thompson GR; Department of Internal Medicine, Division of Infectious Diseases and the Department of Medical Microbiology and Immunology, UC-Davis Medical Center, Sacramento, California, USA., Slavin MA; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia., Maertens JA; Department of Microbiology, Immunology, and Transplantation, KULeuven, Leuven, Belgium.; Department of Hematology, UZ Leuven, Leuven, Belgium., Dadwal SS; Division of Infectious Disease, Department of Medicine, City of Hope National Medical Center Duarte, Duarte, California, USA., Rahav G; Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel., Hazel S; Clinical Operations, Independent/Former Amplyx Pharmaceuticals Inc, San Diego, California, USA.; Clinical Operations, Former Pfizer Global Research and Development, Inc, New York, New York, USA., Almas M; Department of Statistics, Global Biometrics and Data Management, Pfizer Inc, New York, New York, USA., Jakate A; Clinical Pharmacology, Pfizer Inc, New York, New York, USA., Pypstra R; Clinical Development, Pfizer Inc, New York, New York, USA.
Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2025 Dec 24; Vol. 81 (5), pp. e302-e309.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40203286
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hodges+MR%22">Hodges MR</searchLink>; Independent/Former Amplyx Pharmaceuticals Inc, San Diego, California, USA.; Pfizer Central Research and Development (PGRD), La Jolla, San Diego, California, USA.<br /><searchLink fieldCode="AU" term="%22Tawadrous+M%22">Tawadrous M</searchLink>; Clinical Development, Pfizer Inc, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Cornely+OA%22">Cornely OA</searchLink>; Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.; Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Thompson+GR%22">Thompson GR</searchLink>; Department of Internal Medicine, Division of Infectious Diseases and the Department of Medical Microbiology and Immunology, UC-Davis Medical Center, Sacramento, California, USA.<br /><searchLink fieldCode="AU" term="%22Slavin+MA%22">Slavin MA</searchLink>; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Maertens+JA%22">Maertens JA</searchLink>; Department of Microbiology, Immunology, and Transplantation, KULeuven, Leuven, Belgium.; Department of Hematology, UZ Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Dadwal+SS%22">Dadwal SS</searchLink>; Division of Infectious Disease, Department of Medicine, City of Hope National Medical Center Duarte, Duarte, California, USA.<br /><searchLink fieldCode="AU" term="%22Rahav+G%22">Rahav G</searchLink>; Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel.<br /><searchLink fieldCode="AU" term="%22Hazel+S%22">Hazel S</searchLink>; Clinical Operations, Independent/Former Amplyx Pharmaceuticals Inc, San Diego, California, USA.; Clinical Operations, Former Pfizer Global Research and Development, Inc, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Almas+M%22">Almas M</searchLink>; Department of Statistics, Global Biometrics and Data Management, Pfizer Inc, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Jakate+A%22">Jakate A</searchLink>; Clinical Pharmacology, Pfizer Inc, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Pypstra+R%22">Pypstra R</searchLink>; Clinical Development, Pfizer Inc, New York, New York, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229203213%22">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</searchLink> [Clin Infect Dis] 2025 Dec 24; Vol. 81 (5), pp. e302-e309.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9203213 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6591 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210584838%22">10584838 </searchLink><i>NLM ISO Abbreviation: </i>Clin Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40203286
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/cid/ciaf185
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e302
    Titles:
      – TitleFull: Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hodges MR
      – PersonEntity:
          Name:
            NameFull: Tawadrous M
      – PersonEntity:
          Name:
            NameFull: Cornely OA
      – PersonEntity:
          Name:
            NameFull: Thompson GR
      – PersonEntity:
          Name:
            NameFull: Slavin MA
      – PersonEntity:
          Name:
            NameFull: Maertens JA
      – PersonEntity:
          Name:
            NameFull: Dadwal SS
      – PersonEntity:
          Name:
            NameFull: Rahav G
      – PersonEntity:
          Name:
            NameFull: Hazel S
      – PersonEntity:
          Name:
            NameFull: Almas M
      – PersonEntity:
          Name:
            NameFull: Jakate A
      – PersonEntity:
          Name:
            NameFull: Pypstra R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 12
              Text: 2025 Dec 24
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1537-6591
          Numbering:
            – Type: volume
              Value: 81
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
              Type: main
ResultId 1